FibroGen, Inc (FGEN) to Release Quarterly Earnings on Monday
FibroGen, Inc (NASDAQ:FGEN) is scheduled to announce its earnings results after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million. On average, analysts expect FibroGen to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of FibroGen, Inc (NASDAQ:FGEN) opened at $55.75 on Friday. The company has a current ratio of 6.21, a quick ratio of 6.21 and a debt-to-equity ratio of 0.39.
In other FibroGen news, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $40.74, for a total value of $81,480.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company’s stock, valued at $1,222,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $56.13, for a total transaction of $2,168,638.68. Following the completion of the sale, the chief executive officer now directly owns 3,144,573 shares of the company’s stock, valued at $176,504,882.49. The disclosure for this sale can be found here. Insiders sold 553,118 shares of company stock valued at $28,645,321 over the last three months. Insiders own 14.90% of the company’s stock.
A number of research analysts recently commented on the stock. Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC reissued a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research report on Friday, July 21st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $65.67.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/fibrogen-inc-fgen-to-release-quarterly-earnings-on-monday/1677014.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.